Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Benserazide hydrochloride [JAN]
RN: 14919-77-8
UNII: B66E5RK36Q
InChIKey: ULFCBIUXQQYDEI-UHFFFAOYSA-N

Note

  • An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.

Molecular Formula

  • C10-H15-N3-O5.Cl-H

Molecular Weight

  • 293.705
 

Classification Codes

  • Drug / Therapeutic Agent
  • Mutation Data
* denotes mobile formatted website

Links to Resources


Search for this InChIKey on the Web

Names and Synonyms

Name of Substance

  • Benserazide hydrochloride
  • Benserazide hydrochloride [JAN]

Synonyms

  • Benserazide HCl
  • Benserazide hydrochloride
  • CCRIS 5092
  • DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazine hydrochloride
  • EINECS 238-991-9
  • Ro 4-4602/001
  • UNII-B66E5RK36Q

Systematic Names

  • 2'-(2,3,4-Trihydroxybenzyl)-DL-serinohydrazide monohydrochloride
  • Benzerazide hydrochloride
  • DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, monohydrochloride (9CI)
  • Serine, 2-(2,3,4-trihydroxybenzyl)hydrazide, monohydrochloride, DL-

Registry Numbers

CAS Registry Number

  • 14919-77-8

FDA UNII

  • B66E5RK36Q

Other Registry Numbers

  • 14046-64-1
  • 31796-68-6

System Generated Number

  • 0014919778

Molecular Formulas

Molecular Formula

  • C10-H15-N3-O5.Cl-H

Molecular Formula Fragments

  • C10-H15-N3-O5
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

1S/C10H15N3O5.ClH/c11-6(4-14)10(18)13-12-3-5-1-2-7(15)9(17)8(5)16;/h1-2,6,12,14-17H,3-4,11H2,(H,13,18);1H

InChIKey

ULFCBIUXQQYDEI-UHFFFAOYSA-N

Smiles

c1(c(c(c(O)cc1)O)O)CNNC([C@@H](CO)N)=O.Cl

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 1700mg/kg (1700mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 62, 1977.
mouse LD50 oral 5gm/kg (5000mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 62, 1977.
mouse LD50 subcutaneous 3300mg/kg (3300mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.
rat LD50 intraperitoneal 2150mg/kg (2150mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.
rat LD50 oral 5300mg/kg (5300mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 2069, 1979.
rat LD50 subcutaneous 2910mg/kg (2910mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 11, Pg. 181, 1980.